Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05075824 · ClinicalTrials.gov registry record · Phase 2

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

A Phase 2 study of Sickle Cell Disease, sponsored by Hoffmann-La Roche.

Active
Registry status
Phase 2
Development phase
90
Enrollment target
20
Study locations

NCT05075824 is a Phase 2 study of Sickle Cell Disease that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 90 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05075824, a Phase 2 study of Sickle Cell Disease, is active but no longer recruiting, sponsored by Hoffmann-La Roche.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.

Conditions Studied

Sickle Cell Disease

Interventions

  • DRUG Placebo
  • DRUG Crovalimab

Study Locations (20)

Other

  • HEMORIO - Rio de Janeiro
  • Hospital Samaritano - São Paulo
  • CHU Henri Mondor - Créteil
  • International Cancer Institute (ICI) - Eldoret
  • Gertrude's Children Hospital - Nairobi
  • Hopital Nini - Tripoli
  • Amsterdam UMC Location VUMC - Amsterdam
  • Charlotte Maxeke Johannesburg Hospital - Johannesburg

São Paulo

  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu - Botucatu
  • Hospital das Clínicas Faculdades Médicas de Ribeirão Preto - Ribeirão Preto
  • Hospital de Base de Sao Jose do Rio Preto - São José do Rio Preto
  • Beneficencia Portuguesa de Sao Paulo - São Paulo

Michigan

  • Children's Hospital of Michigan - Detroit

Mississippi

  • Mississippi Center for Advanced Medicine - Madison

New York

  • Icahn School of Medicine at Mount Sinai - New York

North Carolina

  • East Carolina University - Greenville

Estado de Bahia

  • Hospital Sao Rafael - HSR - Salvador

Rio Grande do Sul

  • Hospital das Clinicas - UFRGS - Porto Alegre

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2022-03-09
Est. Completion 2026-03-31
Phase Phase 2

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05075824

The ClinicalTrials.gov registry entry for NCT05075824 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (69% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05075824 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, São Paulo, Michigan.

Frequently Asked Questions

What is clinical trial NCT05075824 about?

NCT05075824 is a clinical study titled "A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)". This study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.

What is the current status of trial NCT05075824?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2022-03-09. Estimated completion is 2026-03-31.

What conditions does trial NCT05075824 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT05075824?

The interventions under investigation include: Placebo (DRUG), Crovalimab (DRUG).

Who is sponsoring clinical trial NCT05075824?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05075824 being conducted?

This trial has 20 study locations across Michigan, Mississippi, New York, North Carolina, Estado de Bahia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.